OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

HangonI have gone for it!still would like your gut feeling.

tabasco, I really do not know.
However, I'm still in - and bought a few (to av. Dn. at 8p+),
Financially they are sound, so they could buy-in some short-term eye-candy to divert the Market's focus. By widening their appeal their expertise with the FDA would be invaluable and they've been pretty smart with Sanofi- the money is Paid, even if Trovax "fails" -
We're not there yet, but then "earlier trials" would be shams and I can't see that being so. OXB messed-up the "end-points" - and that's their undoing. Seems rather severe.
Glad to read you're "in" again, did you benefit from the rise to 10p, or was that all you?
This is a risky Market and this is a risky stock, BUT I think there is value there - I just hope it's a lot more than current 10p - I suspect we could see 50p only if these Trials are Positive....but I prefer the acquisition route, even though it diverts ...at least it will give Management something to do while the Trials work-through (so it's not a Bad Plan, IMHO). Now is "probably the right time" to go a-buying; with many Bio's in the mire.

Hangon I have friends still in on this one and still optimisticthey have taken a hitand like you averaged downwhich is the way I playI have never made money on thesealthough missed the big drop by luckbought on the 18th august @ 11.20p there is something about the stock.think the percentage is in our favour at these levelsalthough product means high risk?

What a difference a day makes!

tabasco - yes indeedy - but even if Trovax proves worthless for its current treatment - there are yet other angles for it. I suspect that was why Sanofi wanted the technology -

These are "early days" for Gene therapy - it's cutting-edge stuff, I understand.

Also, OXB has other treatments, but you need to read-up for details...everyone is focussed on this Trial . . . . . and that has caused a big upset.
+Glad to read you're in at 11p - a small profit already, perhaps evens with charges/spread?
FWIW I'd wait, there is no real NEWS, and it's reaction (bounce), to over-selling . . . . may take a few months more to reach, say 15p . . .
...then any better news will let it ride-up 19p ( it doesn't like 20p!).....then it's anyone's guess...the Market might push hard, but I fear folks will sell at 25p - 35p (depending where their average is) . . . . missing any longer-term upsides.
BUT there are no g'tees here, it seems.....we've been badly shocked and that takes time to repair...oh deary.


I hope they widen their portfolio, spend some cash to create a broad business - - if it works they are sitting pretty - if not then they had their best shot.
PS Today's rise may be due to an Analysists meeting/presentation which could interest Institutions to invest further. Worth reading also Troval.com on the trials.

Genethera would not bid for Oxford Biomedica as it is not credible


LONDON, Sept 3 LONDON, Sept 3 (Reuters) - Genethera Inc , the US-based veterinary diagnostics company, announced Wednesday that it has decided not to proceed with an offer for Oxford BioMedica Plc .

The British biotech company last month spurned a 35 pence all-share takeover bid by Genethera -- pitched at a 300 percent premium at the time -- describing it as not credible.

Oxford BioMedica shares closed at 10.5 pence on Tuesday.

Following the rejection, the US company, which had a market capitalisation of $230,000 while Oxford BioMedica was worth 46.5 million pounds or $87 million at the time the offer was made, had said it was considering its options.

I suspect Genethera has a reason - but it "looks Bonkers" - as I suggestyed at the time
- Like a local Chippy bidding for MacDonalds!

OXB is conserving its cash and the Trial is still on-going - all that happened was the prospect of further doses appear to be unnecessary. It looks as though about six treatments is about right.

Until the data is gone-through this remains risky - but no-more risky than at 24p - except the sp is under half, so the "risk" is somewhat less also, based on a "risk reward" ratio.

DYOR as always.

it would be nice to report Director Purchases were "stonking-good" indications - yet some of these purchases are very much below my "Excitement level" - 50k.

+When you think these guys are paid 100k, a 10k purchase is little more than 1Month's wage - and at these prices, it has to be a "steal" - so there.

+Still it's a combined good effort, - yet the sp fell 4% today - Ah well.

I almost felt the directors clubbed together today just to try and bolster the sp

Director-purchases ( en-masse), are caused by legal requirements such that Dirs cannot buy during a "closed period" - that really happens quite often, like when results are about to be released, expectation of a big order or bad news anticipated when one of their customers nis in difficulty. OXB isn't likley to have some of these, but there are enough places where "News" might prevent Director dealing, within say 2 months of any News that might lead to a sp movement.

As I posted yesterday - the amounts are not all that spectacular; but nevertheless welcome. . . .at least they aren't Selling - that's some comfort, eh?

There were four sells of 50k, resulting in a small drop in sp. today.

EDIT (6Oct08)-12.5% fall - yet buys are 2x Sells . . . . never understood this game.
EDIT (13Oct08)-New Director given 150k-worth of "incentive"...Grr.
EDIT (30Oct08)- Shares says "sell", now 5p and slipping despite market-upturn.

Reasonably good New-Year News - US-Patent dispute has been thrown out, although as I read the RNS, seems the complainer can register another one within 14-days - but why would they?
Begs the Q why they did in the first place, or were they hopeful of some out-of Court settlement - all very odd.
Virtually zero effect on Sp, so I guess the strong bad-vibes on Trovax prevail and won't impress investors at least until there is some good data from the Trial, as it ramps down. It is very disapointing to see this investment fall to such low-levels as it was 25p(June08) having been somewhat higher.
DYOR

I too am a hangon with much faith in this one for a variety of reasons and rather like PDX (another British Company) it could well be a tenbagger.

Oakapples, what's yr take on PDX ? - as I recall it's a steam pump, what used to be called an injector ( Railway locos use them), so I don't see that 1)it's novel and 2) needed....although I know many punters believed it worth paying 5 for 1p stock. Do you see special virtue in their business?...for it occurs to me that they should be selling like hot-cakes to the "specialist" industries...yet sales are miserably tiny....
Mind-you my belief in OXB has been severly dented, with Execs in hibernation, so it seems!

Expect a BIG movement in the next 7 days - back to July levels.

?? Why ??

you're sounding like me!!

Why?

RESULTS DATE: 12 MARCH 2009

Oxford, UK - 25 February 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces today that it will be releasing its preliminary results for the twelve months ended 31 December 2008 on Thursday, 12 March 2009.



Analyst meeting: An analyst briefing will be held at 09:30 am on Thursday, 12 March 2009 at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.



Web cast: Simultaneously to the analyst briefing at 09:30 am, there will be a live audio web cast of the presentation. To connect to the web cast facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:20 am) before the start of the briefing. This will also be available for replay shortly after the presentation.

Nice rise of 25%. Can't see any reason why but seems to follow the trend of some stocks atm. Perhaps MM's are starting to mark some of these up at last.

45% is a nice mark-up eh. I find similar movement with PDX and GFM which have been dormant for too long.